Şunu aradınız:: transthyretin (İngilizce - Maltaca)

tafamidis meglumine is a specific stabilizer of transthyretin.
tafamidis meglumine hu stabilizzatur speċifiku għal transthyretin.

the active substance in vyndaqel, tafamidis, is a transthyretin stabilizer.
is-sustanza attiva f’vyndaqel, it-tafamidis, hija stabilizzatur tat-transtiretin.

vyndaqel was more effective than placebo at treating patients with transthyretin amyloidosis.
vyndaqel kien aktar effettiv mill-plaċebo fil-kura ta' pazjenti li jbatu minn transtiretin amilojdosi.

in patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily.
f'pazjenti bi transtiretin amilojdosi, il-proteina fid-demm li tissejjaħ transtiretin hija difettuża u titkisser malajr.

vyndaqel was compared with placebo (a dummy treatment) in 128 patients with transthyretin amyloidosis.
vyndaqel tqabbel ma’ plaċebo (kura finta) f’128 pazjent li jbatu minn b’transtiretin amilojdosi.

treatment should be initiated by and remain under the supervision of a physician knowledgeable in the management of patients with transthyretin amyloid polyneuropathy.
it-trattament għandu jinbeda minn, u jibqa’ taħt is-superviżjoni ta’, tabib speċjalizzat u esperjenzat fl- immaniġjar ta’ pazjenti bil-polinewropatija tat-tip transthyretin amyloid.

tafamidis binds non-cooperatively to the two thyroxine binding sites on the native tetrameric form of transthyretin preventing dissociation into monomers.
tafamidis jitgħaqqad mingħajr kooperazzjoni maż-żewġ siti fejn jeħel thyroxine fuq il-forma tetrameric ta’ transthyretin preżenti mit-twelid u jiprevjeni id-dissoċjazzjoni f’monomers.

it attaches to transthyretin, which prevents the protein from breaking up, thereby stopping the formation of amyloid and slowing down the progression of the nerve disease.
din teħel ma’ transtiretin, li tipprevjeni l-proteina milli tinkiser, u għalhekk twaqqaf il-formazzjoni ta’ amilojd u tnaqqas il- progressjoni tal-marda tan-nervituri.

vyndaqel is used to delay nerve damage caused by transthyretin amyloidosis, a hereditary disease in which fibres called amyloid build up in tissues around the body including around the nerves.
vyndaqel jintuża sabiex jittardja l-ħsara fin-nervituri kkawżata minn transtiretin amilojdosi, marda ereditarja li fiha l-fibri msejħa amilojdi jinġemgħu fit-tessuti ta’ madwar il-ġisem fosthom madwar in- nervituri.

that physicians are encouraged to enter patients in the transthyretin amyloidosis outcome survey (thaos) and provided with details how to enroll patients into this international disease registry
li t-tobba huma mħeġġa biex idaħħlu pazjenti fl-istħarriġ dwar ir-riżultat ta’ transthyretin amyloidosis (thaos) u huma provduti bid-dettalji ta’ kif għandhom jirreġistraw il-pazjenti f’dan ir-reġistru internazzjonali tal-marda.

tafamidis meglumine should be added to the standard of care for the treatment of the transthyretin familial amyloid polyneuropathy (ttr-fap) patient.
tafamidis meglumine għandu jiżdied mal-istandard tal-kura għall-kura ta’ pazjent b’polinewropatija amilojde familjali transtiretin (ttr-fap, transthyretin familial amyloid polyneuropathy).

that patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to vyndaqel since there is limited knowledge about the clinical safety due to the rare nature of transthyretin amyloidosis.
li l-pazjenti għandhom jiġu avżati biex jinfurmaw lit-tabib dwar l-avvenimenti avversi u li t- tobba / spiżjara għandhom jirrapportaw reazzjonijiet avversi li jistgħu ikunu relatati ma vyndaqel peress li hemm għarfien limitat dwar is-sigurtà klinika minħabba n-natura rari ta’ amyloidosis ta’ transthyretin.

the dissociation of the transthyretin tetramer to monomers is the rate limiting step in the pathogenesis of ttr amyloid polyneuropathy, also known as ttr familial amyloid polyneuropathy (ttr-fap).
id- dissoċjazzjoni tat-tetramer ta’ transthyretin minn mal-monomers hija l-punt li tillimita r-rata tal- patoġenesi tal-polinewropatija amyloid tat-tip ttr, magħrufa wkoll bħala polinewropatija amyloid tat-tip ttr familjali (ttr-fap).

because the number of patients with transthyretin amyloidosis is low, the disease is considered ‘rare’, and vyndaqel was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 28 august 2006.
minħabba li n-numru ta’ pazjenti bi transtiretin amilojdosi huwa wieħed baxx, il-marda hija meqjusa bħala ‘rari’, u vyndaqel ġie denominat bħala ‘mediċina orfni’ (mediċina użata f’mard rari) fit-28 ta’ awwissu 2006.